Unimed Reports Solid Operational Performance Despite Revenue Decline in H1 2026

Tunis, Tunisia – Unimed (Unité de Fabrication de Médicaments), a leading pharmaceutical laboratory, has released its interim financial statements for the period ending June 30, 2026. Despite a decline in export revenues and an increase in exceptional charges, the company demonstrated robust operational performance during the first half of the year.

Revenue Trends: Domestic Growth Offsets Export Contraction

Total revenues for the first half of 2026 stood at 64.492 MTND, down approximately 10.8% from 72.322 MTND in the same period of 2025.

Domestic Market: Sales within Tunisia showed slight growth, reaching 51.213 MTND.
Exports: Export revenues contracted significantly by 39.0%, falling to 13.278 MTND.

According to company management, the sharp drop in exports is primarily attributed to a decline in activity with a major contract manufacturing client who did not renew orders during the reporting period.

Operational Profitability Remains Strong

Despite the top-line pressure, Unimed’s operational results improved. The operating profit rose to 20.612 MTND, compared to 17.837 MTND in the first half of 2025. This improvement was driven by effective control of operating expenses.

Net Profit Decline Due to Exceptional Charges

The net profit for the period decreased by 15.2% to 8.819 MTND. This decline was largely influenced by ordinary losses totaling 6.569 MTND, which included:

A definitive loss of 4.400 MTND related to a settlement agreement with the tax administration following an audit.
A loss of 1.800 MTND from the write-off of obsolete inventory.

Investor Outlook: Short-Term Concerns Amid Q3 Weakness

Looking ahead, investors may face short-term concerns given the performance in the third quarter. Q3 revenue fell by 24.7% to 32.158 MTND. This continued revenue contraction could weigh on investor sentiment, particularly among those with short-term investment horizons, despite the company’s underlying operational resilience.